Articles from Multidisciplinary Association for Psychedelic Studies (MAPS)

SAN JOSE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is partnering with the HoloMind Institute to deliver its International Psychedelic Therapy Training Program in Poland, a first for the country. From October 6–12, 2025, 60 clinicians from around the world will gather to learn the foundational knowledge of psychedelic-assisted therapies.

SAN JOSE, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, today announced that its Board of Directors has selected Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors. Aldworth and Ali have been interim Co-Executive Directors since March 2025, following Kris Lotlikar’s transition from Executive Director to Secretary of the Board of Directors. MAPS Founder and President, Rick Doblin, will continue to guide research initiatives and international projects.

SAN JOSE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder (PTSD). Today, the FDA made this CRL publicly available for the first time, providing transparency into the agency’s decision-making process.

SAN JOSE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization (CRO) for MJP2, a Phase 2 study examining inhaled cannabis for the treatment of Posttraumatic Stress Disorder (PTSD) in Veterans. MJP2 is funded by a $12.9 million grant from the Michigan Veteran Marijuana Research Grant Program.

SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) --  The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the launch of its enhanced Virtual Trip video conference platform featuring the first selection of videos from Psychedelic Science 2025 (PS2025). Last month, the conference brought together more than 8,000 attendees from all 50 states and dozens of countries across six continents to the Colorado Convention Center in Denver, Colorado. As the psychedelic movement synthesizes decades of progress, challenges, and hard-won lessons to shape the strategic path forward, the fifth installment of the Psychedelic Science conference series — which MAPS has hosted since 2010 — centered on the theme of "The Integration."

SAN JOSE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is bringing its International Therapist Education Program (ITE) to Ukraine. The event is organized in collaboration with the nonprofit Ukrainian Psychedelic Research Association (UPRA) and will take place from April 28 to May 4 in Lviv, Ukraine.

SAN JOSE, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization that has led the psychedelic movement since 1986, today announced a search for its next Executive Director.

Artist-Curated Playlists and Psychedelic Education Come Together to Inspire Safe, Intentional Exploration

DENVER, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Psychedelic Science 2025 (PS2025), the leading psychedelic conference, hosted by Multidisciplinary Association for Psychedelic Studies (MAPS), will be returning to Denver from June 16-20, 2025 at the Colorado Convention Center. Featuring over 500 expert speakers across 12 educational stages and hands-on workshops, this event is designed for professionals and enthusiasts alike, with a focus on therapists and healthcare providers. Speaker submissions, scholarship applications, and creative submissions will be accepted through Friday, December 13. Please visit the FAQ page to learn more.

SAN JOSE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase 2 study of smoked cannabis in Veterans for the treatment of PTSD (MJP2) to proceed. Initially placed on partial clinical hold by the FDA in 2021, MJP2 is a randomized, placebo-controlled study of 320 Veterans suffering from moderate to severe PTSD who have previously used cannabis. Funded by the Michigan Veteran Marijuana Research Grant Program, the study is designed to investigate the inhalation of high THC dried cannabis flower, versus placebo cannabis, with the daily dose being self-titrated by participants.

SAN JOSE, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- A decade after it was founded as a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation (MAPS PBC) has announced the successful close of an oversubscribed Series A financing of more than $100 million, led by Helena, alongside a name change to Lykos Therapeutics and new visual identity. Read more from Lykos Therapeutics here.

SAN JOSE, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from two published Phase 3 studies as well as numerous earlier trials. The nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS) created MAPS PBC in 2014 to advance the research and drug development program for investigational MDMA-assisted therapy for PTSD.

SAN JOSE, Calif., Nov. 11, 2023 (GLOBE NEWSWIRE) -- In honor of Veterans Day, the Multidisciplinary Association for Psychedelic Studies (MAPS) is highlighting a series of insightful discussions focused on critical Veterans’ issues from its breakthrough conference, hosted in June 2023 and now available online through Psychedelic Science 2023: The Virtual Trip. This curated collection of sessions from the conference Veterans stage is part of MAPS’ ongoing commitment to supporting and advocating for Veterans living with PTSD.